High-density lipoprotein: What is the best way to measure its antiatherogenic potential?

Expert Opinion on Medical Diagnostics

Volumn 2, Issue 7, 2008, Pages 773-788

  Remaley, Alan T ^a   Warnick, G Russell ^b  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b Berkeley Heart Lab Inc   (United States)

Author keywords

Assay; Atherosclerosis; Cholesterol; High density lipoproteins

Indexed keywords

ABC TRANSPORTER A1; APOLIPOPROTEIN A1; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PARAOXON; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; SIMVASTATIN; TORCETRAPIB;

ANTIBODY AFFINITY; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; BIOASSAY; CAPILLARY ELECTROPHORESIS; CHOLESTEROL METABOLISM; CONGESTIVE HEART FAILURE; ELECTROSPRAY MASS SPECTROMETRY; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; ISCHEMIC HEART DISEASE; LIPOPROTEIN METABOLISM; LIQUID CHROMATOGRAPHY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PRECIPITATION; PROTEIN AGGREGATION; PROTEIN FUNCTION; PROTEIN POLYMORPHISM; PROTEIN TRANSPORT; REVIEW; SEPARATION TECHNIQUE; TANGIER DISEASE; TWO DIMENSIONAL GEL ELECTROPHORESIS; ULTRACENTRIFUGATION;

EID: 55349125780     PISSN: 17530059     EISSN: 17530067     Source Type: Journal    
DOI: 10.1517/17530059.2.7.773     Document Type: Review

References (159)

1. Gofman JW, Lindgren FT, Elliott H. Ultracentrifugal studies of lipoproteins of human serum. J Biol Chem 1949;179:973-9
2. Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955;34:1345-53
3. Warnick GR, Nauck M, Rifai N. Evolution of methods for measurement of HDL-cholesterol: from ultracentrifugation to homogeneous assays. Clin Chem 2001;47:1579-96
4. Langlois MR, Blaton VH. Historical milestones in measurement of HDL-cholesterol: impact on clinical and laboratory practice. Clin Chim Acta 2006;369:168-78
5. Sethi AA, Amar M, Shamburek RD, Remaley AT. Apolipoprotein AI mimetic peptides: possible new agents for the treatment of atherosclerosis. Curr Opin Investig Drugs 2007;8:201-12
6. Chhabria MT, Suhagia BN, Brahmkshatriya PS. HDL elevation and lipid lowering therapy: current scenario and future perspectives. Recent Patents Cardiovasc Drug Discov 2007;2:214-27
7. Shah PK. Apolipoprotein A-I/HDL infusion therapy for plaque stabilization-regression: a novel therapeutic approach. Curr Pharm Des 2007;13:1031-8
8. Brown BG, Zhao XQ, Cheung MC. Should both HDL-C and LDL-C be targets for lipid therapy? A review of current eveidence. J Clin Lipidol 2007;1:88-94
9. Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target: a systematic review. JAMA 2007;298:786-98
10. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-22
11. Tchoua U, D'Souza W,, Mukhamedova N, et al. The effect of cholesteryl ester transfer protein overexpression and inhibition on reverse cholesterol transport. Cardiovasc Res 2008;77:732-9
12. Nissen SE, Nicholls SJ, Wolski K, et al. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA 2008;299:1547-60
13. Van Lenten BJ, Wagner AC, Navab M, et al. Lipoprotein inflammatory properties and serum amyloid A levels but not cholesterol levels predict lesion area in cholesterol-fed rabbits. J Lipid Res 2007;48:2344-53
14. Ueda M, Sethi AA, Freeman LA, et al. High density lipoproteins: overview and update on new findings from diagnostics to therapeutics. J Clin Ligand Assay 2006;28:216-32
15. Havel RJ, Kane JP. Introduction: structure and metabolism of plasma lipoproteins. In: Scriver CR, Beaudet al, Sly WS, Valle D, editors, The metabolic and molecular bases of inherited diseases. New York: McGraw Hill; 1995. p. 1841-50
16. Law SW, Lackner KJ, Fojo SS, Hospattankar A, Monge JC, Brewer HB Jr. The molecular biology of human apoA-I, apoA-II, apoC-II and apoB. Adv Exp Med Biol 1986; 201:151-162.
17. Anantharamaiah GM, Brouillette CG, Engler JA, et al. Role of amphipathic helixes in HDL structure/function. Adv Exp Med Biol 1991;285:131-40
18. Catte A, Patterson JC, Bashtovyy D, et al. Structure of spheroidal HDL particles revealed by combined atomistic and coarse grained simulations. Biophys J 2007;94:2306-19
19. Lund-Katz S, Liu L, Thuahnai ST, Phillips MC. High density lipoprotein structure. Front Biosci 2003;8:d1044-54
20. Papadopoulos NM. Abrnomal lipoprotein patterns in human serum as determined by agarose gel electrophoresis. Clin Chem 1979;25:1885-7
21. Barrans A, Jaspard B, Barbaras R, et al. Pre-beta HDL: structure and metabolism. Biochim Biophys Acta 1996;1300:73-85
22. Sviridov D, Nestel PJ. Genetic factors affecting HDL levels, structure, metabolism and function. Curr Opin Lipidol 2007;18:157-63
23. Gwynne JT. High-density lipoprotein cholesterol levels as a marker of reverse cholesterol transport. Am J Cardiol 1989;64:10G-17G
24. Zannis VI, Chroni A, Krieger M. Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL. J Mol Med 2006;84:276-94
25. Nofer JR, Remaley AT. Tangier disease: still more questions than answers. Cell Mol Life Sci 2005;62:2150-60
26. Yancey PG, Bortnick AE, Kellner-Weibel G, et al. Importance of different pathways of cellular cholesterol efflux. Arterioscler Thromb Vasc Biol 2003;23:712-9
27. Rothblat GH, de IL-M, Atger V, et al. Cell cholesterol efflux: integration of old and new observations provides new insights. J Lipid Res 1999;40:781-96
28. Ng DS. Insight into the role of LCAT from mouse models. Rev Endocr Metab Disord 2004;5:311-8
29. Cavelier C, Lorenzi I, Rohrer L, von EA. Lipid efflux by the ATP-binding cassette transporters ABCA1 and ABCG1. Biochim Biophys Acta 2006;1761:655-66
30. Williams DL, Connelly MA, Temel RE, et al. Scavenger receptor BI and cholesterol trafficking. Curr Opin Lipidol 1999;10:329-39
31. van der Steeg WA, Kuivenhoven JA, Klerkx AH, et al. Role of CETP inhibitors in the treatment of dyslipidemia. Curr Opin Lipidol 2004;15:631-6
32. Calabresi L, Gomaraschi M, Franceschini G. Endothelial protection by high-density lipoproteins: from bench to bedside. Arterioscler Thromb Vasc Biol 2003;23:1724-31
33. Mineo C, Deguchi H, Griffin JH, Shaul PW. Endothelial and antithrombotic actions of HDL. Circ Res 2006;98:1352-64
34. Rader DJ. Mechanisms of disease: HDL metabolism as a target for novel therapies. Nat Clin Pract Cardiovasc Med 2007;4:102-9
35. Vuilleumier N, Charbonney E, Fontao L, et al. Anti-apolipoprotein A-I IgG are associated with high oxidized low-density lipoprotein levels in acute coronary syndrome. Clin Sci (Lond) 2008; In press
36. Valiyaveettil M, Kar N, Ashraf MZ, et al. Oxidized high-density lipoprotein inhibits platelet activation and aggregation via scavenger receptor BI. Blood 2008;111:1962-71
37. Wang WQ, Merriam DL, Moses AS, Francis GA. Enhanced cholesterol efflux by tyrosyl radical-oxidized high density lipoprotein is mediated by apolipoprotein AI-AII heterodimers. J Biol Chem 1998;273:17391-8
38. Francis GA, Oram JF, Heinecke JW, Bierman EL. Oxidative tyrosylation of HDL enhances the depletion of cellular cholesteryl esters by a mechanism independent of passive sterol desorption. Biochemistry 1996;35:15188-97
39. Shaul PW, Mineo C. HDL action on the vascular wall: is the answer NO? J Clin Invest 2004;113:509-13
40. Mineo C, Shaul PW. HDL stimulation of endothelial nitric oxide synthase: a novel mechanism of HDL action. Trends Cardiovasc Med 2003;13:226-31
41. Anantharamaiah GM, Mishra VK, Gather DW, et al. Structural requirements for antioxidative and anti-inflammatory properties of apolipoprotein A-I mimetic peptides. J Lipid Res 2007;48:1915-23
42. Ansell BJ, Fonarow GC, Navab M, Fogelman AM. Modifying the anti-inflammatory effects of high-density lipoprotein. Curr Atheroscler Rep 2007;9:57-63
43. Kelly JL, Kruski AW. Density gradient ultracentrifugation of serum lipoproteins in a swinging bucket rotor. Methods Enzymol 1986;128:170-80
44. Blix G, Tiselius A, Svensson H. Lipids and polysaccharides in electrophoretically seperated blood serum proteins. J Biol Chem 1941;137:485-94
45. Kunkel HG, Slater RJ. Lipoprotein patterns of serum obtained by zone electrophoresis. J Clin Invest 1952;31:677-84
46. Beaumont JL, Carlson LA, Cooper GR, et al. Classification of hyperlipidaemias and hyperlipoproteinaemias. Bull World Health Organ 1970;43:891-915
47. Van MA, De GY, Vanderveiken F, et al. A modified method for phenotyping of hyperlipoproteinaemia on agarose electrophoresis. Clin Chim Acta 1974;55:225-34
48. Greenspan P, Mao FW, Ryu BH, Gutman RL. Advances in agarose gel electrophoresis of serum lipoproteins. J Chromatogr A 1995;698:333-9
49. Conlon DR, Blankstein LA, Pasakarnis PA, et al. Quantitative determination of high-density lipoprotein cholesterol by agarose gel electrophoresis. Clin Chem 1979;25:1965-9
50. Nauck M, Winkler K, Marz W, Wieland H. Quantitative determination of high-, low-, and very-low-density lipoproteins and lipoprotein(a) by agarose gel electrophoresis and enzymatic cholesterol staining. Clin Chem 1995;41:1761-7
51. Okamoto Y, Tanaka S, Nakano H. Direct measurement of HDL cholesterol preferable to precipitation method. Clin Chem 1995;41:1784
52. Burstein M, Samaille J. Sur une nouvelle methode de dosage du cholesterol lie aux α et aux ß lipoproteins du serum. Clin Chim Acta 1958;3:320-7
53. Burstein M, Scholnick HR, Morfin R. Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. J Lipid Res 1970;11:583-95
54. Lopes-Virella MF, Stone P, Ellis S, Colwell JA. Cholesterol determination in high-density lipoproteins separated by three different methods. Clin Chem 1977;23:882-4
55. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502
56. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993;269:3015-23
57. Warnick GR, Remaley AT. Measurement of cholesterol in plasma and other body fluids. Curt Atheroscler Rep 2001;3:404-11
58. Warnick GR, Albers JJ. Heparin - Mn2+ quantitation of high-density-lipoprotein cholesterol: an ultrafiltration procedure for lipemic samples. Clin Chem 1978;24:900-4
59. Burstein M, Samaille J. Sur un dosage rapide du cholesterol lie aux α- et aux ß-1ipoproteines du serum. Clin Chim Acta 1960;5:609
60. Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977;62:707-14
61. Castelli WP, Garrison RJ, Wilson PW, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986;256:2835-8
62. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8-15
63. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97
64. Abell LL, Levy BB, Brodie RB, Kendall FC. Simplified method for the estimation of total cholesterol in serum, and the demonstration of its specificity. J Biol Chem 1952;195:357-66
65. Kimberly MM, Leary ET, Cole TG, Waymack PP. Selection, validation, standardization, and performance of a designated comparison method for HDL-cholesterol for use in the cholesterol reference method laboratory network. Clin Chem 1999;45:1803-12
66. Kakuyama T, Kimura S, Hasiguchi Y. Fully automated determination of HDL-cholesterol from human serum with Hitachi 911 [abstract]. Clin Chem 1994;40:A1104
67. Sugiuchi H, Uji Y, Okabe H, et al. Direct measurement of high-density lipoprotein cholesterol in serum with polyethylene glycol-modified enzymes and sulfated alpha-cyclodextrin. Clin Chem 1995;41:717-23
68. Harris N, Galpchian V, Thomas J, et al. Three generations of high-density lipoprotein cholesterol assays compared with ultracentrifugation/dextran sulfate-Mg2+ method. Clin Chem 1997;43:816-23
69. Halloran P, Roetering H, Pisani T, et al. Reference standardization and analytical performance of a liquid homogeneous high-density lipoprotein cholesterol method compared with chemical precipitation method. Arch Pathol Lab Med 1999;123:317-26
70. Izawa S, Okada M, Matsui H, Horita Y. A new direct method for measuring HDL-cholesterol which does not produce any biased values. J Med Pharm Sci 1997;37:1385-8
71. Lawlor J, Pelczar D, Sane R, Siek G. Performance characteristics of the RDI homogeneous HDL cholesterol assay [abstract]. Clin Chem 1998;44:A79
72. Sampson ML, Aubry A, Csako G, Remaley AT. Triple lipid screening test: a homogeneous sequential assay for HDL-cholesterol, total cholesterol, and triglycerides. Clin Chem 2001;47:532-9
73. McMillan TA, Warnick GR. Interlaboratory proficiency survey of cholesterol and high-density lipoprotein cholesterol measurement. Clin Chem 1988;34:1629-32
74. Warnick GR, Wood PD. National Cholesterol Education Program recommendations for measurement of high-density lipoprotein cholesterol: executive summary. The National Cholesterol Education Program Working Group on Lipoprotein Measurement. Clin Chem 1995;41:1427-33
75. Kadri N, Douville P, Lachance P. Monoclonal paraprotein may interfere with the Roche direct HDL-C Plus assay. Clin Chem 2002;48:964
76. Nauck M, Marz W, Wieland H. New immunoseparation-based homogeneous assay for HDL-cholesterol compared with three homogeneous and two heterogeneous methods for HDL-cholesterol. Clin Chem 1998;44:1443-51
77. Lackner KJ, Schmitz G. beta-VLDL of patients with type III hyperlipoproteinemia interferes with homogeneous determination of HDL-cholesterol based on polyethylene glycol-modified enzymes. Clin Chem 1998;44:2546-8
78. Roberts WL, Leary ET, Lambert TL, et al. Falsely low direct HDL-cholesterol results in a patient with dysbetalipoproteinemia. Clin Chem 2000;46:560-2
79. Simo JM, Castellano I, Ferre N, et al. Evaluation of a homogeneous assay for high-density lipoprotein cholesterol: limitations in patients with cardiovascular, renal, and hepatic disorders. Clin Chem 1998;44:1233-41
80. Okada M, Matsui H, Ito Y, Fujiwara A. Direct measurement of HDL cholesterol: method eliminating apolipoprotein E-rich particles. J Clin Lab Anal 2001;15:223-9
81. The prevalence study. In: The lipid research clinics population studies data book. Volume 1. Bethesda, MD: National Institute of Health; 1980. p. 76-81
82. National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994;89:1333-445
83. Erhardt LR, Gotto A Jr. The evolution of European guidelines: changing the management of cholesterol levels. Atherosclerosis 2006;185:12-20
84. Zweig MH. Apolipoproteins and lipids in coronary artery disease. Analysis of diagnostic accuracy using receiver operating characteristic plots and areas. Arch Pathol Lab Med 1994;118:141-4
85. Hoeg JM, Klimov AN. Cholesterol and atherosclerosis: "the new is the old rediscovered". Am J Cardiol 1993;72:1071-2
86. Gofman JW, De Lalla O, Glazier F, et al. The serum lipoprotein transport system in health metabolic disorders, atherosclerosis and coronary heart disease. J Clin Lipidol 2007;1:104-41
87. Hirano T, Ito Y, Saegusa H, Yoshino G. A novel and simple method for quantification of small, dense LDL. J Lipid Res 2003;44:2193-201
88. Holvoet P. Oxidized LDL and coronary heart disease. Acta Cardiol 2004;59:479-84
89. Schaefer EJ, Asztalos Bf. Where are we with high-density lipoprotein raising and inhibition of cholesteryl ester transfer for heart disease risk reduction? Curr Opin Cardiol 2007;22:373-8
90. Asztalos BF, Horvath KV, Kajinami K, et al. Apolipoprotein composition of HDL in cholesteryl ester transfer protein deficiency. J Lipid Res 2004;45:448-55
91. Warnick GR, Cheung MC. Measurement and clinical significance of high-density lipoprotein subclasses. In: Rifai N, Warnick GR, Dominiczak MH, editors. Handbook of lipoprotein testing. Washington, DC: American Association of Clinical Chemistry (AACC) Press; 2000. p. 311-28
92. Gofman JW, Young W, Tandy R. Ischemic heart disease, atherosclerosis, and longevity. Circulation 1966;34:679-97
93. Anderson DW, Nichols AV, Pan SS, Lindgren FT. High density lipoprotein distribution. Resolution and determination of three major components in a normal population sample. Atherosclerosis 1978;29:161-79
94. Blanche PJ, Gong EL, Forte TM, Nichols AV. Characterization of human high-density lipoproteins by gradient gel electrophoresis. Biochim Biophys Acta 1981;665:408-19
95. Cheung MC, Brown BG, Wolf AC, Albers JJ. Altered particle size distribution of apolipoprotein A-I-containing lipoproreins in subjects with coronary artery disease. J Lipid Res 1991;32:383-94
96. Saku K, Liu R, Ohta T, et al. Plasma HDL levels are regulated by the catabolic rate of large particles of lipoprotein containing apo-A-I. Biochem Biophys Res Commun 1994;200:557-61
97. Asztalos BF, Demissie S, Cupples LA, et al. LpA-I, LpA-I:A-II HDL and CIT-risk: The Framingham Offspring Study and the Veterans Affairs HDL Intervention Trial. Atherosclerosis 2006;188:59-67
98. Sundaram GS, Mackenzie SL, Sodhi HS. Preparative isoelectric focusing of human serum high-density lipoprotein (HDL3). Biochim Biophys Acta 1974;337:196-203
99. Fielding CJ, Fielding PE. Two-dimensional nondenaturing electrophoresis of lipoproteins: applications to high-density lipoprotein speciation. Methods Enzymol 1996;263:251-9
100. Asztalos BF, Sloop CH, Wong L, Roheim PS. Two-dimensional electrophoresis of plasma lipoproreins: recognition of new apo A-I-containing subpopulations. Biochim Biophys Acta 1993;1169:291-300
101. Asztalos BF, Roheim PS, Milani RL, et al. Distribution of ApoA-I-containing HDL subpopulations in patients with coronary heart disease. Arterioscler Thromb Vasc Biol 2000;20:2670-6
102. Asztalos BF, Batista M, Horvath KV, et al. Change in alpha1 HDL concentration predicts progression in coronary artery stenosis. Arterioscler Thromb Vasc Biol 2003;23:847-52
103. Asztalos BF, Cupples LA, Demissie S, et al. High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 2004;24:2181-7
104. Asztalos BF, Collins D, Cupples LA, et al. Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol 2005;25:2185-91
105. Lamon-Fava S, Herrington DM, Reboussin DM, et al. Plasma levels of HDL subpopulations and remnant lipoproteins predict the extent of angiographically-defined coronary artery disease in postmenopausal women. Arterioscler Thromb Vasc Biol 2008;28:575-79
106. Mahley RW, Huang Y, Weisgraber KH. Putting cholesterol in its place: apoE and reverse cholesterol transport. J Clin Invest 2006;116:1226-9
107. Warnick GR, McNamara JR, Boggess CN, et al. Polyacrylamide gradient gel electrophoresis of lipoprotein subclasses. Clin Lab Med 2006;26:803-46
108. Johansson J, Carlson LA, Landou C, Hamsten A. High density lipoproteins and coronary atherosclerosis. A strong inverse relation with the largest particles is confined to normotriglyceridemic patients. Arterioscler Thromb 1991;11:174-82
109. Morals J, Muniz N, Di Guida O. Evaluation of HDL subclasses using the Lipoprint HDL System. Clin Chem 2006;52:A118
110. Deng D, Tain X, Quin H. Microfluidic chip seperation of HDL subclasses improving cardiovascular risk assessment. Clin Chem 2007;53:A45
111. Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med 2006;26:847-70
112. Otvos JD, Collins D, Freedman DS, et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 2006;113:1556-63
113. Mora S, Szkdo M, Orvos JD, et al. LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 2007;192:211-7
114. Kulkarni KR. Cholesterol profile measurement by vertical auto profile method. Clin Lab Med 2006;26:787-802
115. Chapman MJ, Goldstein S, Lagrange D, Lapland PM. A density gradient ultracentrifugal procedure for the isolation of the major lipoprotein classes from human serum. J Lipid Res 1981;22:339-58
116. Okazaki M, Usui S, Fukui A, et al. Component analysis of HPLC profiles of unique lipoprotein subclass cholesterols for detection of coronary artery disease. Clin Chem 2006;52:2049-53
117. Hirayama S, Miida T, Miyazaki O, Aizawa Y. Pre beta1-HDL concentration is a predictor of carotid atherosclerosis in type 2 diabetic patients. Diabetes Care 2007;30:1289-91
118. Schaefer EJ, McNamara JR. Routine diagnostic testing for apoA-I, apo-B, Lp(a), and LDL cholesterol in clinical laboratories. Clin Lab Sci 1994;7:205-8
119. Walldius G, Jungner I. Apolipoprotein A-I versus HDL cholesterol in the prediction of risk for myocardial infarction and stroke. Curr Opin Cardiol 2007;22:359-67
120. Contois J, McNamara JR, Lammi-Keefe C, et al. Reference intervals for plasma apolipoprotein A-1 determined with a standardized commercial immunoturbidimetric assay: results from the Framing, ham Offspring Study. Clin Chem 1996;42:507-14
121. Walldius G, Jungner I, Holme I, et al. High apolipoprotein B, low apolipoprorein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001;358:2026-33
122. Gotto AM Jr, Whitney E, Stein EA, et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/ TexCAPS). Circulation 2000;101:477-84
123. Marcovina SM, Albers JJ, Henderson LO, Hannon WH. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. III. Comparability of apolipoprotein A-I values by use of international reference material. Clin Chem 1993;39:773-81
124. Ferretti G, Bacchetti T, Negre-Salvayre A, et al. Structural modifications of HDL and functional consequences. Atherosclerosis 2006;184:1-7
125. Shao B, Oda MN, Vaisar T, et al. Pathways for oxidation of high-density lipoprotein in human cardiovascular disease. Curr Opin Mol Ther 2006;8:198-205
126. Wu Z, Wagner MA, Zheng L, et al. The refined structure of nascent HDL reveals a key functional domain for particle maturation and dysfunction. Nat Struct Mol Biol 2007;14:861-8
127. Zheng L, Settle M, Brubaker G, et al. Localization of nitration and chlorination sites on apolipoprotein A-I catalyzed by myeloperoxidase in human atheroma and associated oxidative impairment in ABCA1-dependent cholesterol efflux from macrophages. J Biol Chem 2005;280:38-47
128. Zheng L, Nukuna B, Brennan ML, et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest 2004;114:529-41
129. Calabresi L, Sirtori CR, Paoletti R, Franceschini G. Recombinant apolipoprotein A-IMilano for the treatment of cardiovascular diseases. Curt Atheroscler Rep 2006;8:163-7
130. Fruchart JC, Ailhaud G. Apolipoprotein A-containing lipoprotein particles: physiological role, quantification, and clinical significance. Clin Chem 1992;38:793-7
131. Kothapalli D, Fuki I, Ali K, et al. Antimitogenic effects of HDL and APOE mediated by Cox-2-dependent IP activation. J Clin Invest 2004;113:609-18
132. Higashihara M, Kinoshita M, Teramoto T, et al. The role of apoE in inhibitory effects of apoE-rich HDL on platelet function. FEBS Lett 1991;282:82-6
133. Birjmohun RS, linga-Thie GM, Kuivenhoven JA, et al. Apolipoprotein A-II is inversely associated with risk of future coronary artery disease. Circulation 2007;116:2029-35
134. Frohlich J, Dobiasova M. Fractional esterification rate of cholesterol and ratio of triglycerides to HDL-cholesterol are powerful predictors of positive findings on coronary angiography. Clin Chem 2003;49:1873-80
135. Dobiasova M, Adler L, Ohta T, Frohlich J. Effect of labeling of plasma lipoproteins with [(3)H]cholesterol on values of esterification rate of cholesterol in apolipoprotein B-depleted plasma. J Lipid Res 2000;41:1356-7
136. Mackness B, Davies GK, Turkie W, et al. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol 2001;21:1451-7
137. Mackness B, Durrington P, McElduff P, et al. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 2003;107:2775-9
138. Karlsson H, Leanderson P, Tagesson C, Lindahl M. Lipoproteomics II: mapping of proteins in high-density lipoprorein using two-dimensional gel electrophoresis and mass spectrometry. Proteomics 2005;5:1431-45
139. Hortin GL, Shen RF, Martin BM, Remaley AT. Diverse range of small peptides associated with high-density lipoprotein. Biochem Biophys Res Commun 2006;340:909-15
140. Watanabe J, Chou KJ, Liao JC, et al. Differential association of hemoglobin with proinflammatory high density lipoproteins in athetogenic/ hyperlipidemic mice. A novel biomarker of atherosclerosis. J Biol Chem 2007;282:23698-707
141. Vaisar T, Pennathur S, Green PS, et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 2007;117:746-56
142. Schmitz G, Liebisch G, Langmann T. Lipidomic strategies to study structural and functional defects of ABC-transporters in cellular lipid trafficking. FEBS Lett 2006;580:5597-610
143. van MG, Leeflang BR, Liebisch G, et al. The European lipidomics initiative: enabling technologies. Methods Enzymol 2007;432:213-32
144. Lamarche B, Rashid S, Lewis GF. HDL metabolism in hypertriglyceridemic states: an overview. Clin Chim Acta 1999;286:145-61
145. Sparks DL, Davidson WS, Lund-Katz S, Phillips MC. Effects of the neutral lipid content of high density lipoprotein on apolipoprotein A-I structure and particle stability. J Biol Chem 1995;270:26910-7
146. Greene DJ, Skeggs JW, Morton RE. Elevated triglyceride content diminishes the capacity of high density lipoprotein to deliver cholesteryl esters via the scavenger receptor class B type I (SR-BI). J Biol Chem 2001;276:4804-11
147. Nofer JR, Assmann G. Atheroprotective effects of high-density lipoprotein-associated lysosphingolipids. Trends Cardiovasc Med 2005;15:265-71
148. Argraves KM, Argraves WS. HDL serves as a SlP signaling platform mediating a multitude of cardiovascular effects. J Lipid Res 2007;48:2325-33
149. Nofer JR, Bot M, Brodde M, et al. FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 2007;115:501-8
150. White J, Guerin T, Swanson H, et al. Diabetic HDL-associated myristic acid inhibits acetylcholine-induced nitric oxide generation by preventing the association of endothelial nitric oxide synthase with calmodulin. Am J Physiol Cell Physiol 2008;294:C295-305
151. Kolleck I, Schlame M, Fechner H, et al. HDL is the major source of vitamin E for type II pneumocytes. Free Radic Biol Med 1999;27:882-90
152. Aviram M. HDL - associated paraoxonase 1 (PON1) and dietary antioxidants attenuate lipoprotein oxidation, macrophage foam cells formation and atherosclerosis development. Pathophysiol Haemost Thromb 2006;35:146-51
153. Terasaka N, Wang N, Yvan-Charvet L, Tall AR. High-density lipoprotein protects macrophages from oxidized low-density lipoprotein-induced apoptosis by promoting efflux of 7-ketocholesterol via ABCG1. Proc Natl Acad Sci USA 2007;104:15093-8
154. Chirinos JA, Zambrano JP, Chakko S, et al. Ability of serum to decrease cellular acylCoA:cholesterol acyl transferase activity predicts cardiovascular outcomes. Circulation 2005;112:2446-53
155. Gomaraschi M, Calabresi L, Rossoni G, et al. Anti-inflammatory and cardioprotective activities of synthetic high-density lipoprotein containing apolipoprotein A-I mimetic peptides. J Pharmacol Exp Ther 2008;324:776-83
156. Ansell BJ, Navab M, Hama S, et al. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 2003;108:2751-6
157. Navab M, Hama SY, Hough GP, et al. A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J Lipid Res 2001;42:1308-17
158. McMahon M, Grossman J, FitzGerald J, et al. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 2006;54:2541-9
159. Kalantar-Zadeh K, Kopple JD, Kamranpour N, et al. HDL-inflammatory index correlates with poor outcome in hemodialysis patients. Kidney Int 2007;72:1149-56